DOCSLIB.ORG

Blood Glucose Monitoring Performance of “Roche Accu-Check Go” Glucometer Device at Moderately High Altitude

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Blood Glucose Monitoring Performance of “Roche Accu-Check Go” Glucometer Device at Moderately High Altitude Turkish Journal of Endocrinology and Metabolism, (2005) 4 : 115-118 ORIGINAL ARTICLE Blood Glucose Monitoring Performance of “Roche Accu-Check Go” Glucometer Device at Moderately High Altitude Habib Bilen* Alpaslan Kılıçaslan** Güngör Akçay* İlyas Çapoğlu* * University of Atatürk,School of Medicine, Department of Internal Medicine, Division of Endocrinology, Erzurum, Turkey ** University of Hacettepe, School of Medicine, Department of Internal Medicine, Ankara, Turkey To evaluate the performance of Roche Accu-check glucometer device compared to reference laboratory measurement in moderately high altitude. Research Design and Methods: Fasting blood glucose measurements were made simultaneously by Accu- check go glucometer device and standard laboratory methods in a group of 204 male and female patients residing in Erzurum, a province in Eastern Turkey with an altitude of 2000 meters. Majority of patients had type 2 diabetes. Results: Average fasting blood glucose levels measured with Accu-check go (101.5; 71-456) were lower compared to reference values (102.5; 69-456), with no statistically significant difference. Also, there were no significant differences between the two methods with regard to measured values below and above the threshold level of 126. The type of diabetes and gender had no effect on measurements. Conclusions: Slightly lower glucose levels observed with Accu-check go at a moderately high altitude of 2000 meters can be explained on the basis of oxidoreductase method used. However, absence of any significant difference suggests that the ability of Accu-check go to detect hypoglycemia at this altitude at an early stage is not compromised. Keywords: Accu-check go, altitude, blood glucose monitoring system Introduction conducted at the Endocrinology Unit, Atatürk University, Erzurum, Turkey. Erzurum with an Hypoglycemia is a major complication in the altitude of greater than 2000 meters is a popular treatment of diabetes. Self-monitoring of blood winter sports center with a long winter season. glucose (SMBG) is an important tool both for the improved glucose control and in the prevention of hypoglycemia (1). SMGB allows self-monitoring Research Design and Methods of blood glucose when used appropriately. A total of 204 patients between 19 and 71 years of However the performance of these devices are age mostly residing in Erzurum were included in affected by a number of factors including altitude, this study. Majority of the patients had type 2 temperature, oxygen saturation of blood, low diabetes. Blood sampling for fasting blood glucose atmospheric pressure, humidity, and a change in measurements was done in the morning hours at hematocrit value, as well as user-related factors (2-7). the laboratory of Endocrinology Unit by nurses. The room temperature was approximately 20°C. In this study, our objective was to evaluate the Capillary blood glucose was measured by “Roche performance of Roche Accu-check glucometer Accu-check go (serial no: GJ0492680, Roche, device compared to reference laboratory measure- Mannheim, Germany)” glucometer device, which ments in moderately high altitude. The study was utilizes a photometric measurement technique based on oxidoreductase method. Approximately 1.5 μl of full blood (fresh capillary or venous, Li- or Correspondence address: NH4-heparin or EDTA) is required for measure- Habib Bilen University of Atatürk,School of Medicine, ments by Accu-check go, and the reading is Department of Internal Medicine, Division of Endocrinology, available in 5 seconds. A venous blood sample was Erzurum, Turkey Tel : +90 442 236 12 12 drawn quickly thereafter for laboratory measure- E-mail : [email protected] ment of plasma glucose with an Olympus AU 2700 115 ORIGINAL ARTICLE analyzer (serial no: 1110268). Barometric pressure cordance between the two measurements was and humidity were constant. Performance of the assessed with kappa constant and the concordance glucometer device was determined by comparison rate was 47%, which is depicted by Bland & with the standard laboratory methods. Patients with Altman plots (Figure 1). As can be seen from the diabetes complication were excluded from the figure, the concordance rate for values below 126 study. Patients who were treated with medications is higher compared to those above it, although chi- that can affect blood glucose levels (e.g. steroids), square test revealed no statistical difference patients who had anemia (serum hematocrit <40%) between the two measurement methods for values and patients who are receiving medications that below and above 126 (p > 0.05). influence glucose measurement by glucometer In Table 2, the relationship between gender and the (e.g. aspirin, vitamin C) were also excluded. two measurement methods is shown. There were Informed consent was obtained from all patients. 124 female and 80 male patients in the study. The study protocol was approved by the local There were no differences between the two Ethics Committee-Institutional Board, and was methods in terms of gender (p > 0.05). carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki as Majority of the patients had type 2 diabetes (Table 1), revised in 2000. and the effect of the type of diabetes on measu- rements was investigated. Accu-check go and Statistical analysis reference measurements did not differ significantly with respect to the type of diabetes (p > 0.05) Wilcoxon pairwise two-sample test was used due (Table 3). to the abnormal distribution of data. Instead of mean, median values (minimum and maximum) Table 1. Demographic characteristics of patients. were used. Kappa constant was used to assess the AGE concordance between the two measurement met- Male, y (range) 49.5 (21-71) hods with regard to the values observed below and Female, y (range) 45.0 (19-66) above the threshold level of 126. Statistical SEX analysis were performed with SPSS 11.5 and Male, n (%) 80 (39.2) medcalc 6.16. Female, n (%) 124 (60.8) Results TYPE of DM Type 1, n (%) 33 (16.2) The mean age was 46 years (19-71 y). Demo- Type 2, n (%) 171 (83.8) graphic characteristics of the patients are shown in Table 1. The average blood glucose levels Female measured with Accu-check go and reference Type 1, n (%) 20 (16.1) laboratory were 101.5 (71-456) and 102.5 (69-456) Type 2, n (%) 104 (83.9) mg/dl, respectively. The blood glucose values of Male the overall patient group were divided into two: Type 1, n (%) 13 (16.3) those below and above 126 mg/dl. The con- Type 2, n (%) 67 (83.8) Table 2. Comparison of two methods for different sexes. Measurement Gender Median (Min-Max) P value method Reference 100,0 (75,0-444,0) 0,801 (ns) Male (n=80) Accu-check 104,5 (74,0-456,0) Reference 102,5 (71,0-456,0) 0,893 (ns) Female (n=124) Accu-check 101,0 (69,0-432,0) Reference 102,5 (69,0-456,0) Total (n=204) Accu-check 101,5 (71,0-456,0) ns: not significant, P<0,05 is considered significant 116 ORIGINAL ARTICLE Table 3. Comparison of two methods for different diabetes types. Measurement DM Type Median (Min-Max) P value method Reference 111,0 (83,0-450,0) 0,815 (ns) DM Type 1 (n=33) Accu-check 119,0 (81,0-397,0) DM Type 2 Reference 100,0 (71,0-456,0) 0,889 (ns) (n=171) Accu-check 101,0 (69,0-456,0) Reference 102,5 (69,0-456,0) Total (n=204) Accu-check 101,5 (71,0-456,0) ns: not significant, P<0,05 is considered significant 400 the oxidase method at different altitudes and found lower values with increasing altitude (11). 300 +1.96 SD In this study, although slightly lower glucose 200 238,0 values were observed with Accu-check go, the 100 difference was not significant. Since Accu-check Mean 0 go is based on an oxidoreductase method, lower -5,5 -100 values can be explained on the basis of decreased Refferance - Accu_check Refferance - partial oxygen pressure at moderately high alti- -200 -1.96 SD tudes, though the difference was negligible. -249,0 -300 We also evaluated whether Accu-check go -400 measurements differ for values below and above a 50 100 150 200 250 300 350 400 AVERAGE of Refferance and Accu_check threshold level of 126 mg/dl. In contrast to the previous study in which blood glucose levels were Figure 1. Bland & Altman plot diagram of blood glucose values for measured in different groups (8), we found no two measurement methods (within +/- 1.96 standard significant difference. deviation) Factors that can influence the performance of glucometer devices include inadequate exposure to Conclusion capillary blood drop, timing errors, and user errors In this study, we evaluated the performance of (12). In order to minimize the effect of such Roche Accu-check go glucometer device at a factors, glucometer measurements were performed moderately high altitude and found no significant by trained personnel. On the other hand, possible difference between measurements made with effect of other variables such as hematocrit Accu-check go and reference laboratory (p > 0.05). changes, altitude, ambient temperature, humidity, In contrast with a previous study, Accu-check go hypotension, hypertriglyceridemia, hypoxia and values were lower compared to laboratory values low atmospheric pressure cannot be ruled out (8). However in that study, the effect of altitude was completely. In order to eliminate such confounding not assessed. Capillary blood glucose measurement factors patients with a hematocrit value below 40, devices (BGMs) have been shown to produce patients with hypotension, and patients who are lower values under laboratory conditions with being treated with medications that can have an constant humidity and temperature simulating impact on glucose measurements were excluded altitudes greater than 2000 meters (4), in very high from the study.
Load more

Recommended publications
  • Glossary of Common Diabetes Terms
    Glossary of Common Diabetes Terms A1C: a test that reveals exactly how well your blood sugar (glucose) has been controlled over the previous three months Beta cells: cells found in the pancreas that make insulin Blood glucose: also known as blood sugar, glucose comes from food and is then carried through the blood to deliver energy to cells Blood glucose meter: a small medical device used to check blood glucose levels Blood glucose monitoring: the simple blood test used to check the amount of glucose in the blood; a tiny drop of blood, taken by pricking a finger, is placed on a test strip and inserted in the meter for reading Diabetes: the shortened name for diabetes mellitus, the condition in which the pancreas doesn’t produce enough insulin or your body is unable to use insulin to move glucose into cells of the body Diabetic retinopathy: the eye disease that occurs in someone with diabetes when the small blood vessels of the retina become swollen and leak liquid into the retina, blurring vision; it can sometimes lead to blindness Gestational diabetes: the diabetes some women develop during pregnancy; it typically subsides after the baby is delivered, but many women who have had gestational diabetes may develop type 2 diabetes later in life Glucagon: the hormone that is injected into a person with diabetes to raise their blood glucose level when it’s very low (hypoglycemia) Glucose: blood sugar that gives energy to cells Hyperglycemia: also known as high blood glucose, this condition occurs when your blood glucose level is too high;
    [Show full text]
  • Country-Specific Glucose Monitor List
    Country-Specific Glucose Monitor List Country Name: Middle East and Africa (Bahrain, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia (KSA), Sudan, U.A.E.) Important Information This is a non-comprehensive list, current as of November 2016. Absence of a specific glucose monitor or test strips from this list does NOT imply compatibility or incompatibility with EXTRANEAL (Icodextrin) PD solution. Similarly, other glucose-measuring technologies which are not listed below (such as continuous glucose monitoring systems) may or may not be compatible with EXTRANEAL. Always contact the device manufacturer for current information. If the manufacturer cannot provide information regarding compatibility of the device with icodextrin and maltose, Baxter does NOT recommend that EXTRANEAL patients use the product. Baxter reserves the right to change this list without notice and does not represent that it includes all potentially incompatible products. The glucose monitor manufacturers listed have certified to Baxter that they have tested (as per ISO 15197) their monitors with maltose and icodextrin to Baxter’s recommended limits: 278 mg/dL (maltose) and 1094 mg/dL (icodextrin). The manufacturers certified that their “green” monitors, below, showed no interference of blood glucose readings under these conditions, with the exception of the “green” monitors specifically notated 4 for which certification of testing to Baxter’s recommended limits has not yet been received. Please note that the compatibility list below is only for brand-name monitors used with the corresponding brand-name test strip. If a brand-name monitor is used with another manufacture’s test strip, always contact the test strip manufacturer for current information.
    [Show full text]
  • Blood Glucose Meters
    BLOOD GLUCOSE METERS BLOOD DROP SIZE Meters specify how much blood, in microliters, is needed to get an accurate reading. Some meters allow you to reapply blood within a few seconds if your sample size was too small, so you don’t waste a strip. 1.5 1.0 0.8 0.7 FREESTYLE PRECISION NEO Blood Drop Size Blood Drop 0.6 0.5 0.4 0.3 FEATURES: BLOOD SAMPLE SIZE*: 0.6 BATTERY: 2 CR2032 KEY MSRP: $24.99 = audio capability = port light STRIP MSRP: 44¢/strip = backlight = logs insulin dose ($21.99/50 strips) BP = measures both blood + = calculates insulin dose glucose and blood = meter program offers Strips are compatible with the pressure access to certified meter built into the FreeStyle = wireless Bluetooth diabetes educators Libre reader capability = app compatible ADVOCATE = requires user coding * = microliters C advocatemeters.com = can save data to the ** = sold only with 888-469-3579 cloud without having insulin pump to push the data to MSRP = manufacturer’s suggested ADVOCATE REDI-CODE another device retail price. These are PLUS SPEAKING METER = computer download over-the-counter retail FEATURES: capability prices; check with your BLOOD SAMPLE SIZE*: 1.0 K = also tests blood ketones insurance plan for specific BATTERY: 2 AAA P = communicates with coverage and out-of- MSRP: $29.99 insulin pump pocket costs. STRIPS MSRP: 50¢/strip ($24.99/50 strips) ABBOTT DIABETES CARE AGAMATRIX myfreestyle.com agamatrix.com 888-522-5226 866-906-4197 FREESTYLE FREEDOM LITE JAZZ WIRELESS 2 FEATURES: FEATURES: BLOOD SAMPLE SIZE*: 0.3 BLOOD SAMPLE SIZE*: 0.5
    [Show full text]
  • Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients with Type 2 Diabetes: a Prospective Study
    Open Access Original Article DOI: 10.7759/cureus.11195 Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study Ayman Al Hayek 1 , Asirvatham Alwin Robert 1 , Mohamed Al Dawish 1 1. Department of Endocrinology and Diabetes, Prince Sultan Military Medical City, Riyadh, SAU Corresponding author: Ayman Al Hayek, [email protected] Abstract Introduction Self-monitoring of blood glucose (SMBG) plays an important role in diabetes management. The Contour®Next One glucometer is a recent glucometer that delivers blood glucose results by an immediate color indicator to aware users when blood glucose is at a critical high or low. The main purpose of the study was to assess the impact of an application of a blood glucose meter (BGM) having a color range indicator on clinical characteristics and glucose monitoring satisfaction (GMS) among patients having type 2 diabetes (T2D). Methods A total of 85 (male 42 and female 43) patients with T2D were switched to a BGM having smartLIGHT™ target range indicator (blood glucose meters featuring color range indicator) using Contour®Next One glucometer. Demographic data, as well as glycemic control, were collected at baseline and 12 weeks. At the time of the baseline and 12 weeks of the study, a trained interviewer gave the GMS survey questionnaire to every patient in order to collect the glucose monitoring satisfaction. In addition to GMS, a patient’s perceptions of smartLIGHT™ feature satisfaction survey responses were also collected from the patients at the end of the study (12 weeks).
    [Show full text]
  • Country-Specific Glucose Monitor List Kazahhstan 2017
    Список мониторов глюкозы для страны Страна : Казахстан (Kazakhstan) Важная информация Это неполный список , действующий по состоянию на 20 декабря 2017 года . Отсутствие определенного монитора глюкозы или тест -полосок в этом списке НЕ указывает совместимость или несовместимость ПД - раствором препарата EXTRANEAL ( Икодекстрин ). Аналогично , другие технологии измерения глюкозы , которые не перечислены ниже ( например , системы для непрерывного мониторинга глюкозы ), могут или не могут быть совместимы с препаратом EXTRANEAL. Всегда обращайтесь к производителю устройства за актуальной информацией . Если производитель не может предоставить информацию о совместимости устройства с икодекстрином и мальтозой , компания Baxter НЕ рекомендует пациентам , принимающим EXTRANEAL, использовать этот продукт . Baxter оставляет за собой право изменять этот список без предварительных уведомлений и не гарантирует включение в него всех потенциально несовместимых продуктов . Перечисленные производители мониторов глюкозы сертифицированы , то есть компания «Baxter» проверила (согласно ISO 15197) работу их мониторов в присутствии мальтозы и икодекстрина в пределах рекомендованных компанией «Baxter» концентраций : 278 мг / дл (мальтоза ) и 1094 мг / дл (икодекстрин ). Подтверждено , что при таких условиях перечисленные ниже « зеленые » мониторы этих производителей не мешают определению уровня глюкозы в крови , за исключением « зеленых » мониторов , обозначенных специальным значком 4, которые еще не еще проверены на соответствие рекомендованным лимитам компании
    [Show full text]
  • DIABETES MELLITUS Connie J
    Northwest Community Healthcare Paramedic Education Program DIABETES MELLITUS Connie J. Mattera, M.S., R.N., EMT-P Reading assignment: Aehlert Vol. 1 pp 957 – 962 SOP: Diabetic/Glucose Emergencies (p. 26); Peds Diabetic / Glucose Emergencies (p. 76); D10% dosing chart (p.100) OBJECTIVES Upon completing the assigned readings, class and homework questions, each participant will independently do the following with at least an 80% degree of accuracy and no critical errors: 1. Define diabetes mellitus. 2. Discuss the functions of the islets of Langerhans, including the formation and function of insulin, glucagon, and somatostatin. 3. Describe how the body normally metabolizes and controls blood glucose. 4. Compare and contrast the classifications of diabetes including the pathophysiology, onset, clinical presentation and potential complications of type 1, type 2, and gestational diabetes. 5. Identify the classifications, names, and actions of oral diabetes medications and the various types of insulin. 6. Outline the epidemiology and causes of DKA. 7. Sequence the development of dehydration and acidosis in DKA. 8. Separate the signs and symptoms of DKA into those that reflect acidosis and those that reflect dehydration. 9. Differentiate DKA and hyperglycemic, hyperosmolar, non-ketotic syndrome (HHNS). 10. List the precipitating factors for HHNS. 11. Discuss the pathophysiology of hypoglycemia. 12. List the signs and symptoms of hypoglycemia. 13. Describe the body's compensatory mechanisms to hypoglycemia. 14. Anticipate the effects of elevated insulin levels in the body. 15. Give examples of the long-term effects of hyperglycemia on the body systems, including the kidneys, heart and blood vessels, eyes, and nervous system. 16.
    [Show full text]
  • How Should Glucose Meters Be Evaluated for Critical Care
    How Should Glucose Meters Be Evaluated For Critical Care IFCC Working Group GMECC Terms of reference 1 and 2 Submitted to IFCC 10 December 2017 Authors: Cynthia Bowman, WG Chair and editor Laboratory Director, Baystate Health Wing and Noble Hospitals, Springfield, MA, US Sean Cunningham, Assistant editor Consultant Clinical Biochemist (European Specialist Laboratory Medicine EuSpLM), Dublin, IE Robbert Slingerland Clinical Chemist (European Specialist Laboratory Medicine EuSpLM), Department of Clinical Chemistry, Isala, Zwolle, NL Dieter Mesotten Previously: KU Leuven and Dept. Intensive Care Medicine, University Hospitals Leuven Currently: Uhasselt and Dept. Anaesthesiology and Intensive Care Medicine, Kiekenhuis Oos-Limburg, BE Brad S Karon Professor of Laboratory Medicine and Pathology Mayo Clinic, Rochester, MN, US James Nichols Professor of Pathology, Microbiology and Immunology Medical Director of Clinical Chemistry and Point-of-Care Testing Vanderbilt University School of Medicine, Nashville, TN, US 2 IFCC WORKING GROUP WG-GMECC HOW SHOULD GLUCOSE METERS BE EVALUATED IN CRITICAL CARE Chair C. Bowman US Members E. Bigot-Corbel FR S. Cunningham IE E. Guillen Barua PY P. Luppa DE T. Malati IN D. Sacks US R. Slingerland NL B. Solnica PL P. St.Louis CA F. Vanstapel BE R. White AU Corporate Members M. Mulder Roche E. Ntrivalas Nova Biomedical Advisors D. Bruns US B. Clarke US B. Karon US D. Mesotten BE J. Nichols US M. Scott US Corresponding Members Nominated by National Societies DN Bustos Confederación Unificada Bioquímica de la Republica Argentina (CUBRA) M. Rocliffe Australasian Association of Clinical Biochemists I. Barsic Croatian Society of Medical Biochemistry and Laboratory Medicine D. Springer Czech Society of Clinical Biochemistry (CSKB) A.
    [Show full text]
  • Data Collection from Blood Glucose Meter and Anomaly Detection Kan Şekeri Sayacından Veri Toplama Ve Anomali Tespiti
    Karaelmas Fen ve Müh. Derg. 7(2):428-433, 2017 Research Article Karaelmas Fen ve Mühendislik Dergisi Received / Geliş tarihi : 15.12.2016 Journal home page: http://fbd.beun.edu.tr Accepted / Kabul tarihi : 10.02.2017 Data Collection from Blood Glucose Meter and Anomaly Detection Kan Şekeri Sayacından Veri Toplama ve Anomali Tespiti Ali Buldu1* , Kazim Yildiz1 , Eyup Emre Ulku1 , Onder Demir1 , Ufuk Kurgan2 1Marmara University, Department of Computer Engineering, Istanbul, Turkey 2Marmara University Department of Electronics and Computer Education, Istanbul, Turkey Abstract Blood glucose concentration is accepted as a pandemic disease because every day the patient count increases. There are many reasons for blood glucose disease and millions of people are affected. Some people living in big cities and near hospitals can have a continuous treatment, but most people are lack of regular doctor checking which is very important for the health. There some instruments to keep track of the daily blood glucose measurements but they are personal use only. In this project, a personal use only data collector used to collect data for multi patients. Data are stored in a database then doctor or the patient himself can reach and see the trend of the measurement in a meaningful graph. So, regular checking could be minimized in hospitals and also doctors can advise patients about treatment. With this study, blood glucose data are transferred from the measuring device to a recording medium. Although individual use of many devices, with this project a system designed for individual use is employed for more than one patient. Keywords: Computerized instrumentation, Data collection, Diabetes, Medical information systems Öz Kan şekeri hastalığı pandemik bir hastalık olarak kabul edilir; çünkü hasta sayısı her geçen gün artmaktadır.
    [Show full text]
  • Diabetes Life Lines Newsletter, Vol. 32, No. 3, August/September 2018
    University of Georgia Family & Consumer Sciences Volume 32 ♦ Number 3 ♦ August/September 2018 Diabetes Life Lines New Blood Pressure Guidelines that it was better to lower the blood pressure guidelines and start treating Do you have high blood pressure? If you people for high blood pressure sooner didn’t before, you might now. The than later. So what does this mean for all American College of Cardiology (ACC) people? And what does it mean for and the American Heart Association people with diabetes? (AHA) recently changed the definition of high blood pressure, or hypertension Well, for everyone, it means that your (HTN). The chart below shows the old doctor may decide to start you on and new definitions of high blood medication or ask you to make changes in Inside this pressure. A healthy blood pressure is still your lifestyle. For people with diabetes, it issue: 120/80 mm Hg or lower. Under the old is very important to protect your heart. guidelines, if your blood pressure was Remember, having diabetes makes it 140/90 mm Hg or higher, you had high more likely that you will get heart disease. • New Blood blood pressure. Now, if your blood Since high blood pressure increases your Pressure pressure is 130/80 mm Hg or higher, you chances of getting heart disease, your Guidelines have high blood pressure. Let’s say your doctor will want you to do everything you blood pressure is 135/85. Under the old can to get your blood pressure under • Back to School: guidelines, you would not have been told control.
    [Show full text]
  • The Role of Blood Glucose Monitoring in Diabetes Management
    2020 THE ROLE OF BLOOD GLUCOSE MONITORING IN DIABETES MANAGEMENT CONTRIBUTING AUTHORS RUTH S. WEINSTOCK, MD, PHD, FACE, FACP SUNY Distinguished Service Professor; Chief, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine; and Medical Director, Clinical Research Unit and Joslin Diabetes Center at Upstate Upstate Medical University Syracuse, NY GRAZIA ALEPPO, MD, FACE, FACP Professor of Medicine Northwestern University Feinberg School of Medicine Chicago, IL TIMOTHY S. BAILEY, MD, FACE, FACP, CPI President and Chief Executive Officer AMCR Institute Escondido, CA, and Clinical Associate Professor University of California San Diego School of Medicine San Diego, CA RICHARD M. BERGENSTAL, MD Executive Director International Diabetes Center, Park Nicollet/ HealthPartners Minneapolis, MN WILLIAM A. FISHER, PHD Distinguished Professor Emeritus and Adjunct Research Professor Department of Psychology, Western University London, Ontario, Canada DEBORAH A. GREENWOOD, PHD, RN, BC-ADM, CDCES, FADCES President and Owner Deborah Greenwood Consulting Sacramento, CA LAURA A. YOUNG, MD, PHD Associate Professor of Medicine and Director, Endocrinology Fellowship Program University of North Carolina School of Medicine Chapel Hill, NC This publication has been supported by unrestricted educational grants to the American Diabetes Association from Ascensia and Lifescan. The Role of Blood Glucose Monitoring in Diabetes Management is published by the American Diabetes Association, 2451 Crystal Drive, Arlington, VA 22202. Contact: 1-800-DIABETES, professional.diabetes.org. The opinions expressed are those of the authors and do not necessarily reflect those of Ascensia, Lifescan, or the American Diabetes Association. The content was developed by the authors and does not represent the policy or position of the American Diabetes Association, any of its boards or committees, or any of its journals or their editors or editorial boards.
    [Show full text]
  • Summary of Safety and Effectiveness Data
    Summary of Safety and Effectiveness Data I. General Information Device Generic Name: Continuous Glucose Monitor Device Trade Name: FreeStyle Navigator® Continuous Glucose Monitoring System Applicant's Name and Address: Abbott Diabetes Care 1360 South Loop Road Alameda, CA 94502 PMA number: P050020 Date of Panel recommendation: None Date of Notice of Approval to Applicant March 12, 2008 II. Indications for Use The FreeStyle Navigator Continuous Glucose Monitoring System is indicated for continually recording interstitial fluid glucose levels in people (ages 18 and older) with diabetes mellitus for the purpose of improving diabetes management. Readings and alarms about glucose levels from FreeStyle Navigator Continuous Glucose Monitoring System are not intended to replace traditional blood glucose monitoring. Before adjusting therapy for diabetes management based on the results and alarms from the FreeStyle Navigator Continuous Glucose Monitoring System, traditional ® blood glucose tests must be performed. The FreeStyle Navigator Continuous Glucose Monitoring System provides a built-in blood glucose meter to confirm the continuous glucose result. The FreeStyle Navigator Continuous Glucose Monitoring System provides real-time readings, graphs, trends and glucose alarms directly to the user. The FreeStyle Navigator Continuous Glucose Monitoring System is intended to be used in home settings to aid people with diabetes in predicting and detecting episodes of hypoglycemia and hyperglycemia and in clinical settings to aid healthcare professionals in evaluating glucose control. The FreeStyle NavigatorContinuous Glucose Monitoring System is available only by prescription. III. Contraindications The FreeStyle Navigator Continuous Glucose Monitoring System must be removed prior to Magnetic Resonance Imaging. 36 Summary of Safety and Effectiveness Data IV. Warnings and Precautions The warnings and precautions can be found in the FreeStyle Navigator Continuous Glucose Monitoring System labeling.
    [Show full text]
  • Glycaemic Variability and Risk Factors of Pregnant Women with and Without Gestational Diabetes Mellitus Measured by Continuous Glucose Monitoring
    International Journal of Environmental Research and Public Health Article Glycaemic Variability and Risk Factors of Pregnant Women with and without Gestational Diabetes Mellitus Measured by Continuous Glucose Monitoring Martina Gáborová 1,* , Viera Doniˇcová 2, Ivana Baˇcová 1,Mária Pallayová 1 , Martin Bona 1, Igor Peregrim 1, So ˇnaGrešová 1, Judita Štimmelová 1, Barbora Dzugasová 3, Lenka Šalamonová Blichová 4 and Viliam Doniˇc 1 1 Department of Medical Physiology, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Košice, Slovakia; [email protected] (I.B.); [email protected] (M.P.); [email protected] (M.B.); [email protected] (I.P.); [email protected] (S.G.); [email protected] (J.Š.); [email protected] (V.D.) 2 Internal and Diabetology Outpatient Department, Human-Care s.r.o., Affiliated Study Foundation for Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Košice, Slovakia; [email protected] 3 Department of Medical and Clinical Microbiology, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Košice, Slovakia; [email protected] 4 Department of Pathological Physiology, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Košice, Slovakia; [email protected] * Correspondence: [email protected] Citation: Gáborová, M.; Doniˇcová, Abstract: Background: The aim of the study was to compare the continuous glucose monitoring V.; Baˇcová,I.; Pallayová, M.; Bona, M.; (CGM)-determined glycaemic variability (GV) of pregnant women with gestational diabetes mellitus Peregrim, I.; Grešová, S.; Štimmelová, (GDM) and without GDM (CG; control group). The secondary aim was to evaluate the association J.; Dzugasová, B.; Šalamonová between risk factors of diabetes in pregnancy and parameters of glyceamic control.
    [Show full text]